Long-term therapeutic success with multimodal therapy in aggressive prolactinoma

[1]  P. Iglesias,et al.  Giant pituitary adenoma: histological types, clinical features and therapeutic approaches , 2018, Endocrine.

[2]  G. Vitale,et al.  Pasireotide in the treatment of neuroendocrine tumors: a review of the literature. , 2018, Endocrine-related cancer.

[3]  O. Dekkers,et al.  Aggressive pituitary tumours and carcinomas: two sides of the same coin? , 2018, European journal of endocrinology.

[4]  S. Yin,et al.  Treatment of aggressive prolactinoma with temozolomide , 2017, Medicine.

[5]  Antonio Di Ieva,et al.  Aggressive pituitary adenomas—diagnosis and emerging treatments , 2014, Nature Reviews Endocrinology.

[6]  I. McCutcheon,et al.  Feasibility and outcome of re-irradiation in the treatment of multiply recurrent pituitary adenomas , 2014, Pituitary.

[7]  Victor M Montori,et al.  Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. , 2011, The Journal of clinical endocrinology and metabolism.

[8]  S. Lamberts,et al.  The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. , 2004, The Journal of clinical endocrinology and metabolism.

[9]  M. Molitch.  Dopamine Resistance of Prolactinomas , 2004, Pituitary.

[10]  S. Melmed,et al.  Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. , 1997, The Journal of clinical investigation.